相关临床试验
1136
224 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
41
3.6%
已完成
194
17.1%
Enrolling By Invitation
16
1.4%
尚未招募
167
14.7%
招募中
341
30.0%
暂停
1
0.1%
终止
6
0.5%
Unknown
362
31.9%
撤回
8
0.7%
暂无批准数据
- Insilico Medicine dosed the first patient with Rentosertib in the Phase III GENESIS-IPF-3 trial for idiopathic pulmonary fibrosis at Peking Union Medical College Hospital. - The 52-week randomized, double-blind, placebo-controlled study will enroll 320 patients across 47 centers in China, with FVC decline as the primary endpoint. - Rentosertib is a potentially first-in-class small molecule targeting TNIK, a fibrosis pathway identified through AI-driven discovery and never previously linked to fibrosis. - Insilico reported first-half 2026 revenue of about $106 million, a 287% year-over-year increase, and its first profitable half-year since listing.
- Beijing-based neurosurgeon Jin Shanmu, a postdoctoral researcher at Peking Union Medical College Hospital, proved Crouzeix's conjecture, a decades-old problem in numerical linear algebra. - Jin used a 16-hour autonomous run on GPT-5.6-Sol operating on the ChatGPT Work platform while researching transcranial ultrasounds. - Mathematicians Alex Townsend, Anne Greenbaum, and Michel Crouzeix reviewed the manuscript and confirmed the proof was correct, though it is not yet peer-reviewed. - The achievement highlights the growing capability of large language models to solve long-standing mathematical problems without highly specialized training.
- China's rare disease sector is entering a strategic window for biomedical innovation, driven by an expanding diagnosis network and significant unmet medical needs that create momentum for drug development. - The country approved 48 rare disease drugs in 2025, with over 17 developed by Chinese enterprises, while the market is projected to grow from $1.3 billion in 2020 to $25.9 billion by 2030. - PUMCH has launched an AI model called "PUMCHGENESIS" to help doctors identify suspected rare diseases and support physician training, addressing diagnostic challenges in a field with complex clinical manifestations. - Despite progress, 95% of rare diseases still lack effective therapies, highlighting the need for stronger policy incentives, sustainable payment mechanisms, and coordinated innovation ecosystems.
- Hope Medicine has dosed the first patient in a Phase III clinical trial for HMI-115, a first-in-class monoclonal antibody targeting moderate-to-severe endometriosis pain. - HMI-115 represents the first and only non-hormonal therapy globally to reach Phase III development for endometriosis treatment. - The drug previously received Fast Track Designation from the FDA and Breakthrough Therapy Designation from China's NMPA based on positive Phase II results published in The Lancet. - Endometriosis affects approximately 190 million women worldwide, representing a potential market size of US$200 billion with significant unmet medical needs.
- Zemprocitinib, a selective JAK1 inhibitor, met its primary endpoint with 79.1% of patients achieving ACR20 response at Week 24 versus 39.7% for placebo (P < 0.0001). - The Phase III trial enrolled 430 patients with moderate to severe rheumatoid arthritis who had inadequate response to biologic DMARDs. - The drug demonstrated a favorable safety profile with most adverse events being mild to moderate in severity. - This represents the first disclosed Phase III trial results in China for a selective JAK1 inhibitor in this patient population.
- HUTCHMED's Phase III ESLIM-02 trial of sovleplenib successfully met its primary endpoint of durable hemoglobin response rate in adult patients with warm antibody autoimmune hemolytic anemia in China. - The novel spleen tyrosine kinase inhibitor demonstrated rapid and durable responses in wAIHA, the most common form of autoimmune hemolytic anemia accounting for 75-80% of adult cases. - HUTCHMED plans to submit a New Drug Application to China's NMPA in the first half of 2026, marking a potential breakthrough for patients with limited treatment options. - The drug targets Syk, a key component in B-cell receptor and Fc receptor signaling, addressing the pathogenic mechanism of antibody-mediated red blood cell destruction in wAIHA.
- Ractigen Therapeutics has dosed the first patient in an investigator-initiated trial of RAG-18, a small activating RNA therapeutic for Duchenne Muscular Dystrophy at Peking Union Medical College Hospital. - RAG-18 utilizes RNA activation technology to target the UTRN gene and upregulate utrophin protein as a functional replacement for missing dystrophin in DMD patients. - The therapy has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation in 2024, with preclinical data showing effective mitigation of muscle damage. - This first-of-its-kind saRNA approach could potentially treat all DMD patients regardless of specific genetic mutation location, addressing limitations of current exon-skipping therapies.
- Hope Medicine completed a Phase 2 trial of HMI-115, a monoclonal antibody targeting the prolactin receptor, showing statistically significant pain reduction in 108 women with endometriosis. - The 240 mg dose group experienced a 42% reduction in dysmenorrhea pain scores and 52% reduction in non-menstrual pelvic pain compared to baseline without causing typical perimenopausal symptoms. - The treatment maintained normal menstrual patterns and sex hormone levels while showing no treatment-related serious adverse events over the 12-week study period. - Hope Medicine is now communicating with the FDA and China's NMPA to finalize Phase 3 protocols for global studies targeting the $180 billion endometriosis market.
- A novel dual-targeting radiopharmaceutical therapy targeting two cancer cell markers simultaneously demonstrated safety and efficacy in a first-in-human trial with nine advanced adenocarcinoma patients. - The treatment achieved an 88.9% response rate, with patients experiencing either tumor shrinkage or disease stabilization after a single treatment cycle. - The therapy showed strong tumor uptake lasting for days, allowing prolonged radiation damage to cancer cells while causing no noticeable side effects. - Patients reported significant quality of life improvements including reduced pain, better appetite, and overall symptom relief compared to previous treatments.
- SCG Cell Therapy's Phase 1 trial of SCG101, an autologous HBV-specific TCR-T cell therapy, demonstrated sustained clearance of hepatitis B surface antigen in 94% of heavily pre-treated HBV-related liver cancer patients. - The innovative immunotherapy showed promising antitumor activity with 47% of patients experiencing measurable tumor regression, despite all having received at least two prior lines of systemic cancer treatment. - SCG101 exhibited a manageable safety profile with transient liver enzyme elevations and manageable cytokine release syndrome, positioning it as a potential breakthrough for the 250 million people affected by HBV worldwide.
